First Trust Advisors LP purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 43,140 shares of the biopharmaceutical company’s stock, valued at approximately $669,000.
Several other large investors have also made changes to their positions in HALO. William Blair Investment Management LLC increased its stake in Halozyme Therapeutics by 774.0% during the second quarter. William Blair Investment Management LLC now owns 3,538,927 shares of the biopharmaceutical company’s stock worth $60,799,000 after acquiring an additional 3,134,003 shares during the last quarter. Nuveen Asset Management LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $25,530,000. Point72 Asset Management L.P. purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $20,404,000. Invesco Ltd. increased its position in shares of Halozyme Therapeutics by 28.2% during the 2nd quarter. Invesco Ltd. now owns 5,387,409 shares of the biopharmaceutical company’s stock valued at $92,555,000 after purchasing an additional 1,183,551 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Halozyme Therapeutics by 8.0% during the 2nd quarter. BlackRock Inc. now owns 12,625,128 shares of the biopharmaceutical company’s stock valued at $216,900,000 after purchasing an additional 929,980 shares during the last quarter. 85.03% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics stock opened at $18.69 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.17 and a quick ratio of 2.83. The firm has a market capitalization of $2.74 billion, a P/E ratio of -33.38 and a beta of 1.88. Halozyme Therapeutics, Inc. has a 1-year low of $13.24 and a 1-year high of $19.73. The company’s 50-day moving average is $17.17 and its 200 day moving average is $16.42.
HALO has been the subject of a number of analyst reports. BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, November 27th. ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. Barclays upgraded shares of Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and cut their price objective for the company from $17.00 to $16.00 in a research report on Tuesday, November 5th. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $20.50.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Further Reading: What is the QQQ ETF?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.